Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: J Immunol Methods. 2017 Aug 18;451:28–36. doi: 10.1016/j.jim.2017.08.004

Figure 1. NGS-based epitope prediction was utilized to predict the epitopes of therapeutic monoclonal antibodies (trastuzumab and bevacizumab).

Figure 1

(a) trastuzumab binds to human epidermal growth factor receptor HER2 (PDB 1n8z), and (b) bevacizumab binds to vascular endothelial growth factor VEGF-A (PDB 1bj1). Antigen in blue, antibody in grey, and antigen interface residues predicted by PyMOL in brown. Interface residues compared well with reported epitope residues.